This is a computer translation of the original webpage. It is provided for general information only and should not be regarded as complete nor accurate. Close Disclaimer
Skip to main content

Guidance Documents

67 Results
Guidance Documents

DEA-Practitioner Training or Continuing Education Requirement for Registration (EO-DEA182R1)

This is a revision of a previously approved and posted Q&A (EO-DEA182), this is not considered guidance. This Q&A provides information regarding the training requirement included in CAA of 2023. All practitioners, who is not solely a veterinarian, must attest to satisfying the training, credentialing, or educational requirements identified in the CAA in order to obtain a new or renewal DEA registration.

ID: DEA-DC-076
Component Diversion Control Program (DEA)
Date Issued: September 25, 2023
Guidance Documents

Required Training with Respect to Opioid Use Disorder (OUD) for DEA-Registered Practitioners (EO-DEA268)

This guidance document provides information regarding a Drug Enforcement Administration (DEA)-registered practitioner’s attestation of the training requirement in the recently enacted Consolidated Appropriations Act of 2023 (CAA). While specifically targeted to the treatment of or screening for OUD, this training is required for all qualified practitioners applying for or renewing a registration to dispense controlled substances in schedules II-V.

ID: DEA-DC-075
Component Diversion Control Program (DEA)
Date Issued: August 31, 2023
Guidance Documents

Reporting Regulated Transactions Involving Listed Chemicals (EO-DEA280)

This guidance document provides clarification regarding the regulatory requirement for persons engaging in regulated transactions in listed chemicals to report transactions involving an extraordinary quantity, an rare method of payment or delivery, or other circumstances indicating a potential use of listed chemicals in violation of the law. End of
Translation
Click to Translate text after this point
This guidance is being sent via email to all Drug Enforcement Administration (DEA) listed chemical registrants and regulated persons.

ID: DEA-DC-074
Component Diversion Control Program (DEA)
Date Issued: August 30, 2023
Guidance Documents

Revision of Three Previously Posted Q&As relating to Electronic Prescriptions for Controlled Substances (EPCS)(EO-DEA022R1)

This is a revision of previously approved and posted Q&As, that were published on March 31, 2020. DEA-DC-9. This document replaces three of the questions posted within DEA-DC-9 and provides information regarding what EPCS is, remote identity proofing, and if qualified practitioners are allowed to use EPCS to issue prescriptions for CIII-V CS approved by the FDA for MOUD.

ID: DEA-DC-09R1
Component Diversion Control Program (DEA)
Date Issued: July 25, 2023
Guidance Documents

Pharmacist Manual (EO-DEA226)

This Practitioner’s Manual has been prepared by the DEA, Diversion Control Division, as a guide to assist practitioners in their understanding of the federal Controlled Substances Act and its implementing regulations as they pertain to their profession.

ID: DEA-DC-071
Component Diversion Control Program (DEA)
Date Issued: June 14, 2023
Guidance Documents

COVID-19 Flexibility Updates (EO-DEA277)

This document informs DEA registrants impacted by the flexibilities DEA granted during the COVID-19 PHE, which flexibilities will automatically terminate at the conclusion of the COVID-19 PHE on May 11, 2023, and which flexibilities will remain in effect after May 11, 2023 under the Opioid Crisis PHE. The document also informs DEA registrants of newly published proposed rules intended to make some exceptions related to the COVID-19 PHE permanent.

ID: DEA-DC-072
Component Diversion Control Program (DEA)
Date Issued: May 10, 2023
Guidance Documents

Requirement to Use Multiple Single-Sheet DEA Form 222s (Order Forms) When Transferring Schedule I or II Controlled Substances Upon Termination or Transfer of a DEA Registration, or Discontinuing Business Altogether (EO-DEA117)

This guidance document clarifies the requirement for Drug Enforcement Administration (DEA) registrant-transferors to use multiple single-sheet DEA Form 222s (order forms) when transferring schedule I or II controlled substances to a DEA registrant-transferee when the number of items being transferred exceeds the number of lines available on the order form.

ID: DEA-DC-070
Component Diversion Control Program (DEA)
Date Issued: April 26, 2023
Guidance Documents

Disposal of Controlled Substances

This guidance document, will be sent via email to all Drug Enforcement Administration registrants to provide clarification for disposal.

ID: DEA-DC-068
Component Diversion Control Program (DEA)
Date Issued: April 2, 2023